The Lynx Group

ASCO 2015 Highlights

Chicago, IL—In patients with metastatic colorectal cancer (mCRC) with liver-dominant metastases who received first-line FOLFOX (leucovorin, fluorouracil [Adrucil], and oxaliplatin [Eloxatin]) with or without bevacizumab (Avastin) plus selective internal radiation therapy (SIRT) compared with FOLFOX with or without bevacizumab, progression-free survival (PFS) in the liver was extended by 7.9 months, according to the results of the SIRFLOX trial, which were presented at the 2015 American Society of Clinical Oncology (ASCO) meeting.
Read Article

Page 2 of 2

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: